KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Non-Current Liabilities (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $482.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 8.61% year-over-year to $482.8 million, compared with a TTM value of $482.8 million through Dec 2025, down 8.61%, and an annual FY2025 reading of $482.8 million, down 8.61% over the prior year.
  • Total Non-Current Liabilities was $482.8 million for Q4 2025 at Travere Therapeutics, up from $459.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $620.3 million in Q4 2022 and bottomed at -$288.1 million in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $480.2 million, with a median of $519.3 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities crashed 152.45% in 2023, then surged 279.97% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $407.4 million in 2021, then skyrocketed by 52.26% to $620.3 million in 2022, then decreased by 6.86% to $577.8 million in 2023, then decreased by 8.57% to $528.3 million in 2024, then decreased by 8.61% to $482.8 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for TVTX at $482.8 million in Q4 2025, $459.1 million in Q3 2025, and $514.7 million in Q2 2025.